Crizotinib in ALK+ inflammatory myofibroblastic tumors—Current experience and future perspectives

Publisher: John Wiley & Sons Inc

E-ISSN: 1545-5017|65|4|pbc.26920-pbc.26920

ISSN: 1545-5009

Source: PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.65, Iss.4, 2018-04, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract